Dr. Mohler on Overuse of ADT in Prostate Cancer and NCCN Guidelines | OncLive

Dr. Mohler on Overuse of ADT in Prostate Cancer and NCCN Guidelines

April 1, 2016

James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses the use of androgen-deprivation therapy (ADT) for patients with prostate cancer and how the use is reflected in the NCCN guidelines.

James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses the use of androgen-deprivation therapy (ADT) for patients with prostate cancer and how the use is reflected in the NCCN guidelines. Mohler discussed this topic in a talk at the 2016 NCCN Annual Conference.

Mohler says it was interesting for him to go back and try to understand the rationale behind NCCN guidelines regarding ADT in prostate cancer.

Continuous use of ADT has deleterious effects on patients’ morbidity and increases the risk of cardiovascular death. Though it may be easier for a physician to prescribe continuous ADT, Mohler says, intermittent therapy—and the idea that less is better—is more appropriate.

The NCCN guidelines are carefully crafted around this subject and heeds both good data and missing data, according to Mohler.

<<<

View more from the 2016 NCCN Annual Conference


x